Step-Down" Approach May Be Unnecessary

MARCH 01, 2005

High-dose fluticasone versus low-dose flucticasone is no more effective in treating asthma. A study, reported in Chest (January 2005), found that starting individuals with moderate asthma on a high dose of the inhaled steroid and then stepping down to a low dose provides no greater benefit than starting at a low fixed dose.

For the study, the researchers randomly assigned 35 patients to begin inhaled fluticasone propionate at 1000 mcg per day and then to lower the dose to 200 mcg per day, or to start treatment at a fixed dose of 200 mcg.

The results of the study showed that both regimens lowered bronchial hyperresponsiveness and airway inflammation to a similar degree. Furthermore, 8 weeks after stopping fluticasone, inflammation indicators stayed in the normal range in 30% of the patients in both groups.


Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 


Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.